(Q82152072)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

S Morecki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Y Gelfand

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

E Yacovlev

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

O Eizik

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Y Shabat

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

I Sagiv

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

S Slavin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

24 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

838-845

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020024%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2011.198

15 January 2020

exact match

0 references

cites work

Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Graft-versus-host disease: how to translate new insights into new therapeutic strategies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Shared biology of GVHD and GVT effects: potential methods of separation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Prevention and treatment of acute GvHD.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Are there effective new strategies for the treatment of acute and chronic GvHD?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Selective depletion strategies in allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Prophylaxis of acute GVHD: manipulate the graft or the environment?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Elimination of alloreactive T cells using photodynamic therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Effect of KRN7000 on induced graft-vs-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Suppression of primary T-cell responses and induction of alloantigen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG490

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

(5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

(5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Suppression of (5R)-5-hydroxytriptolide (LLDT-8) on allograft rejection in full MHC-mismatched mouse cardiac transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

NK026680, a novel compound suppressive of dendritic cell function, ameliorates mortality in acute lethal graft-versus-host reaction in mice

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021

Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.198

7 January 2021